GLP-compliant repeat-dose toxicology, biodistribution, and genomic integration studies required to position such vaccines for clinical trials were conducted in rabbits and confirmed that a vaccine produced by the RapidResponseTM system was well-tolerated.
Confocal microscopy and biodistribution assays were performed to evaluate the localization and uptake of the FITC-conjugated CPE peptide in established tumor tissue. ❋ Unknown (2010)
However, our stability studies and biodistribution data, along with previous reported investigations on other ❋ Unknown (2010)
In vivo biodistribution experiments revealed high specific BT-474 uptake after 24, 48 and 72 h (64. 68±13.06%ID/g; 71. 71±10.35%ID/g and 85. 18±11.10%ID/g, respectively) with retention of activity for over 120 h. ❋ Unknown (2010)
At late time points, the biodistribution data for 89Zr-DFO-trastuzumab show residual uptake in the bone (4. 79±0.65%ID/g and 6. 86±3.02%ID/g at 72 and 120 h, respectively). ❋ Jason P. Holland Et Al. (2010)
[48] Studies include in vitro and in vivo by Western blot analysis, acute biodistribution studies and immunoPET. ❋ Jason P. Holland Et Al. (2010)
Furthermore, the slight decrease in tumor uptake between 72 and 120 h is consistent with the 9. 6%ID/g decrease in BT-474 tumor uptake observed from the biodistribution studies. ❋ Unknown (2010)
The second presentation described results of a biodistribution comparison of CPX-351 to empty liposomes in a human leukemia xenograft model. ❋ Unknown (2010)
GMP cell bank production and storage, cell bank and viral vector safety testing, viral clearance services, biodistribution studies, analysis of biofluids using immunochemistry based techniques and extensive protein chemistry support including cGMP batch release and stability testing. ❋ Unknown (2010)
Pre-treatment with PU-H71 was followed by biodistribution studies and immunoPET of ❋ Jason P. Holland Et Al. (2010)
For the immunoPET experiments a total of 80-90 µg of trastuzumab was administered, whereas in the biodistribution assays only ❋ Unknown (2010)
Importantly, previous studies in our laboratory using the Focus 120 microPET and "non-saturating" PET radiotracers have demonstrated close agreement between imaging and biodistribution-derived activity concentrations. ❋ Unknown (2010)
• Use established in vivo bioimaging machinery to investigate biodistribution of new formulations ❋ Unknown (2010)
The biodistribution data show that at 24 and 48 h post-injection, tumor uptake in PU-H71-treated mice reached ❋ Unknown (2010)
Yuan Y, Xu F, Tao X, et al. (2009) In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly (ethylene-glycol) - modified PLA (BAB type) triblock copolymer. ❋ Hans-Christian Ingerslev Et Al. (2010)
"Using quantum dots as a model system, we have systematically defined the physicochemical parameters that mediate uptake of nanoparticles by the lung, their biodistribution to tissues, organs and tumors and their clearance from the body," said Frangioni. ❋ Unknown (2010)
The 89Zr-DFO-trastuzumab biodistribution data suggest that a single-dose of PU-H71 induces a sustained effect in terms of HER2/neu and other client oncoprotein degradation for at least 48 h post-administration. ❋ Unknown (2010)
